-- アンテロ・リソーシズ(AR)は水曜日に第1四半期決算を発表し、日次純天然ガス換算生産量が前年同期の34億立方フィート相当から平均39億立方フィート相当に増加したことを明らかにした。 同社のヘッジ前天然ガス販売価格は平均1,000立方フィートあたり5.57ドルで、前年同期の4.01ドルから上昇した。C3+天然ガス液販売価格は平均1バレルあたり37.83ドルで、前年同期の45.65ドルから下落した。 アンテロは1日平均13.8段階の掘削を完了し、2025年の13.4段階から増加した。また、1坑井あたりの掘削日数は9日弱と新記録を樹立し、前年比9%の改善となった。当四半期に販売を開始したマーセラス層の20坑井における水平坑井の平均長さは11,652フィートだった。 同社によると、稼働開始から約60日経過した13坑井は、エタン回収率25%を前提とした場合、1坑井あたり平均日量2,500万立方フィート相当の生産量を達成しており、そのうち液体燃料は日量1,457バレルとなっている。 アンテロ社は、HG買収による四半期全体の生産量増加に支えられ、第2四半期の生産量は平均日量41億立方フィート相当になると見込んでいる。2026年下半期の生産量は平均日量約42億立方フィート相当となり、通年生産量は従来ガイダンスから変更なく日量約41億立方フィート相当になると予想している。
Related Articles
Electro Optic Systems Reports Contract Backlog Growth as of March 31
Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.
Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance
Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.
Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.